Analogous to using similar or identical CD3-binding domains in multiple CD3 TCEs, the same monovalent CD28-binding domain in XmAb808 can be readily coupled with binding domains for other tumor-specific antigens to generate new clinical candidates against a range of cancers (49). This evidence concerns the gene CD28 and neoplasm.